SCHEMBL1908550

SCHEMBL1908550

O=C1CCC(=Cc2ccc(-c3ccccc3)cc2)N1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.50
▸ FAAH O00519 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ PPARG P37231 1/20 0.46
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ EP300 Q09472 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ GSK3A P49840 3/20 0.44
▸ GSK3B P49841 3/20 0.44
▸ PIM1 P11309 2/20 0.43
▸ NLRP3 Q96P20 1/20 0.43
▸ BRD4 O60885 1/20 0.42
▸ F2 P00734 1/20 0.42
▸ PLG P00747 1/20 0.42
▸ ELANE P08246 1/20 0.42
▸ CTSG P08311 1/20 0.42
▸ CMA1 P23946 1/20 0.42
▸ CTRC Q99895 1/20 0.42
▸ KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL598078 1.00 MGLL (0.50) MGLLFAAHPOLBPPARGRAB9A
SCHEMBL5769842 0.80 MGLL (0.65) MGLLFAAHPOLBRAB9ASMN1; SMN2
SCHEMBL290791 0.76 POLB (0.70) MGLLPOLBL3MBTL1GSK3AGSK3B
SCHEMBL1908629 0.75 MGLL (0.64) MGLLFAAHPOLBPPARGEP300
SCHEMBL598742 0.75 MGLL (0.64) MGLLFAAHPOLBPPARGEP300
SCHEMBL100136 0.71 POLB (0.56) MGLLFAAHPOLBL3MBTL1BRD4
Bicarbonate SCHEMBL25171118 0.71 POLB (0.64) MGLLPOLBSMN1; SMN2L3MBTL1GSK3A
SCHEMBL12177758 0.70 PPARG (0.82) POLBPPARGNLRP3KMT2AMAPK1
SCHEMBL97652 0.70 HPGD (0.53) POLBPPARGPIM1BRD4KMT2A
SCHEMBL97651 0.70 HPGD (0.53) POLBPPARGPIM1BRD4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206116-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2015-12-08 — — US disclosed
US-9206116-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2015-12-08 — — US disclosed
US-20150166468-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid NOVARTIS AG (CH) 2015-06-18 — — US disclosed
US-20150166468-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid NOVARTIS AG (CH) 2015-06-18 — — US disclosed
US-8993785-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2015-03-31 — — US disclosed
US-8993785-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2015-03-31 — — US disclosed
US-20140249320-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid NOVARTIS AG (CH) 2014-09-04 — — US disclosed
US-20140249320-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid NOVARTIS AG (CH) 2014-09-04 — — US disclosed
US-8716495-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2014-05-06 — — US disclosed
US-20120142916-A1 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2012-06-07 — — US disclosed
US-8115016-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2012-02-14 — — US disclosed
US-8115016-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2012-02-14 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
WO-2008083967-A2 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2008-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid MME, REN, PAH MGLL 3262/4885FAAH 432/4885POLB 1854/4885
US-20120142916-A1 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID MME, REN, PAH MGLL 3262/4885FAAH 432/4885POLB 1854/4885
US-20140249320-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid MME, REN, PAH MGLL 3262/4885FAAH 432/4885POLB 1854/4885
US-20150166468-A1 Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid MME, REN, PAH MGLL 3262/4885FAAH 432/4885POLB 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback